The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Which patients with NSCLC benefit the most from adjuvant chemo-IO?
Edoardo Garbo, MD, Dana-Farber Cancer Institute, Boston, MA, suggests that patients with non-small cell lung cancer (NSCLC) with high TMB levels, high PD-L1 levels may be safely treated with chemoimmunotherapy in the adjuvant setting without significant concerns for long-term outcomes. In contrast, patients with negative predictors such as KRAS or STK11 mutations may require closer monitoring and consideration of clinical trials or additional adjuvant treatments to potentially improve long-term outcomes. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that if you have a patient with high TMB level, PD-L1, high PD-L1 level, you could be safe in choosing chemo IO in the new adjuvant setting without worrying too much about long-term outcomes. Whereas if you have negative predictors such as KRAS STK11 mutation or KRAS KIF1 mutations you probably need to screen patients for clinical trials in which combos and new agents might improve long-term outcomes for these patients...
I think that if you have a patient with high TMB level, PD-L1, high PD-L1 level, you could be safe in choosing chemo IO in the new adjuvant setting without worrying too much about long-term outcomes. Whereas if you have negative predictors such as KRAS STK11 mutation or KRAS KIF1 mutations you probably need to screen patients for clinical trials in which combos and new agents might improve long-term outcomes for these patients. If you don’t have access to that you probably need to monitor closely your patients and if you have to choose to also add on top of that adjuvant treatment you probably should also add other adjuvant treatment in the equation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
